Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2025-02-24 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI regulations and provides dates and types of meetings. There is no financial data, no report attached or referenced as being published, and no detailed presentation or earnings information included. The document is an announcement of meetings with investors and analysts, which aligns with an Investor Presentation (IP) type, as it relates to investor relations activities and scheduled meetings to discuss company matters. However, since the document only provides a schedule of meetings and does not contain the actual presentation or detailed financial information, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about investor meetings without substantive financial content or presentation materials.
2025-02-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Gland Pharma Limited for Q3 FY 2025. It includes management commentary, financial performance data, operational updates, strategic priorities, and Q&A format typical of earnings call transcripts. The text explicitly mentions it is an "Earnings call Transcript - Q3FY25" and contains detailed discussion of quarterly financial results, business highlights, and forward-looking statements. The length is substantial (15,000 characters), and it contains the full transcript rather than a brief announcement or summary. Therefore, the document fits the category of a Call Transcript (CT).
2025-02-10 English
Copy of Newspaper Publication
Regulatory Filings
2025-02-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events and information. The content is a notification about upcoming investor meetings, not a financial report, earnings release, or any detailed presentation. The document length is short (2527 characters) and it serves as an announcement of scheduled meetings rather than the meetings' content or transcript. This fits the category of Investor Presentation (IP) only if it contained detailed presentation content, but here it is just a schedule notification. It is not a report publication announcement or regulatory filing in the usual sense, but it is a regulatory disclosure about investor meetings. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2025-02-07 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Postal Ballot Notice dated February 7, 2025, issued by Gland Pharma Limited. It is addressed to stock exchanges and shareholders, informing them about a postal ballot process for voting on resolutions related to remuneration commissions for independent directors. The document references compliance with SEBI Listing Regulations and the Companies Act, 2013, and details the voting process, cut-off dates, and the electronic voting mechanism. It does not contain financial statements, audit results, or detailed financial performance data. Instead, it is a formal notice seeking shareholder approval via postal ballot. This type of document is an announcement of a voting process and resolutions to be voted on, not the results or a report of the voting outcome. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) only if it contained results, but since it is a notice before voting, it is best classified as a Proxy Solicitation & Information Statement (PSI) or a Postal Ballot Notice. Given the definitions, the closest match is Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. Confidence is high as the document is clearly a postal ballot notice with detailed voting instructions and proposed resolutions for shareholder approval.
2025-02-07 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement containing the unaudited financial results for the quarter and nine months ended December 31, 2024. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which mandates disclosure of financial results via advertisements. The document itself does not contain detailed financial statements or analysis but is an announcement of the publication of these results in newspapers. The document length is short (1762 characters), and it states that the advertisement is enclosed for information and records. Therefore, this is not the financial report itself but an announcement related to the publication of financial results. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the publication of financial results, not the results themselves or a full interim report.
2025-02-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.